Back to Search
Start Over
Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma
- Source :
- BioFactors. 45:62-68
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Fibroblast growth factors (FGF) 19, 21, and 23 have been reported as functional factors in human metabolic diseases and malignancies. We performed a prospective survey to compare circulating FGF levels in urothelial carcinoma (UC) patients and normal controls. Between 2016 and 2017, 39 patients with UC of the urinary bladder or upper urinary tract who received surgical intervention were included. All the serum samples were obtained before surgeries. The control group included 28 healthy volunteers. Analysis of the circulating FGF19, 21, and 23 levels among all 67 subjects, as well as a subgroup analysis of the 39 UC patients were performed. The median levels of serum FGF19, 21, and 23 in the UC patients were 84.2, 505.3, and 117.6 pg/mL, respectively, which were statistically different from levels found in the healthy controls (P = 0.015
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Urinary bladder
FGF21
Receiver operating characteristic
business.industry
Clinical Biochemistry
Area under the curve
FGF19
Subgroup analysis
General Medicine
Biochemistry
Gastroenterology
End stage renal disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
medicine.anatomical_structure
030220 oncology & carcinogenesis
Internal medicine
medicine
Molecular Medicine
business
Upper urinary tract
Subjects
Details
- ISSN :
- 09516433
- Volume :
- 45
- Database :
- OpenAIRE
- Journal :
- BioFactors
- Accession number :
- edsair.doi...........ec95148d5b233ecb8bbd56c18709ac4f